Fresenius Medical Care (NYSE:FMS) Earns Strong-Buy Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Fresenius Medical Care (NYSE:FMS - Get Free Report) in a research report issued to clients and investors on Tuesday. The brokerage set a "strong-buy" rating on the stock.

A number of other equities analysts also recently commented on FMS. Morgan Stanley restated an "underweight" rating on shares of Fresenius Medical Care in a report on Thursday. Truist Financial increased their price objective on Fresenius Medical Care from $25.00 to $30.00 and gave the stock a "hold" rating in a report on Monday, May 12th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Fresenius Medical Care currently has an average rating of "Hold" and a consensus target price of $27.80.

Fresenius Medical Care Price Performance

NYSE FMS opened at $29.11 on Tuesday. The company has a 50 day simple moving average of $25.08 and a 200-day simple moving average of $23.80. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. The firm has a market capitalization of $17.08 billion, a price-to-earnings ratio of 24.06, a price-to-earnings-growth ratio of 0.76 and a beta of 0.85. Fresenius Medical Care has a 52-week low of $17.93 and a 52-week high of $29.19.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.43 by $0.01. The business had revenue of $5.54 billion during the quarter, compared to analyst estimates of $4.71 billion. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. Equities research analysts predict that Fresenius Medical Care will post 1.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Fresenius Medical Care

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wayfinding Financial LLC acquired a new position in Fresenius Medical Care during the first quarter valued at approximately $25,000. Spire Wealth Management acquired a new position in Fresenius Medical Care during the first quarter valued at approximately $27,000. Smartleaf Asset Management LLC grew its holdings in Fresenius Medical Care by 192.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company's stock valued at $28,000 after purchasing an additional 806 shares during the last quarter. Brooklyn Investment Group grew its holdings in Fresenius Medical Care by 424.5% during the first quarter. Brooklyn Investment Group now owns 1,285 shares of the company's stock valued at $32,000 after purchasing an additional 1,040 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in Fresenius Medical Care by 234.1% during the fourth quarter. Russell Investments Group Ltd. now owns 3,151 shares of the company's stock valued at $71,000 after purchasing an additional 2,208 shares during the last quarter. Institutional investors and hedge funds own 8.37% of the company's stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.